Business Context and Reporting Period
Xeris Biopharma Holdings, Inc. (XERS) is a commercial-stage biopharmaceutical company focused on therapies for chronic endocrine and neurological diseases. The filing covers the fiscal year ended December 31, 2025. The company commercializes three primary products: Recorlev (Cushing's syndrome), Gvoke (severe hypoglycemia), and Keveyis (Primary Periodic Paralysis). It is advancing a Phase 3-ready pipeline product, XP-8121 (once-weekly subcutaneous levothyroxine).
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenue | $291.8 million | $203.1 million | +43.7% |
| Net Income (Loss) | $0.6 million | ($54.8 million) | Turned Profitable |
| Operating Income (Loss) | $24.9 million | ($33.6 million) | +$58.5 million |
| Operating Cash Flow | $28.6 million | ($37.0 million) | Positive |
| Cash and Equivalents | $111.0 million | $71.6 million | +$39.4 million |
| Total Debt (Net) | $220.3 million | $232.1 million | -$11.8 million |
| Accumulated Deficit | ($671.3 million) | ($671.9 million) | Reduced |
Revenue Breakdown (2025): Recorlev ($139.3M, +116.7%), Gvoke ($94.1M, +13.6%), Keveyis ($47.6M, -3.8%).
Material Changes vs. Prior Period
- Profitability Milestone: 2025 marked the company's first year of net income since inception, driven by a 174% improvement in operating income.
- Recorlev Growth: Revenue more than doubled due to a 123.9% increase in volume, offset by a 7.2% unfavorable net pricing impact.
- Keveyis Decline: Revenue decreased 3.8% due to generic competition (Torrent Pharmaceuticals and Rising Pharmaceuticals) and unfavorable pricing, despite a 6.3% volume increase.
- Debt Restructuring: The company converted $15.2 million of 2025 Convertible Notes into common stock in early 2025. Outstanding 2028 Convertible Notes remain at $33.6 million, and a $200 million term loan facility is active.
- Expense Management: Cost of goods sold as a percentage of revenue improved to 15.0% from 18.7% in 2024.
Guidance, Outlook, and Risks
Outlook: Management believes current cash resources are sufficient to sustain operations for at least the next 12 months. The company plans to initiate a Phase 3 clinical trial for XP-8121 in 2026. No specific financial guidance was provided in the text.
Key Risks and Contingencies:
- Patent Litigation: Xeris filed a Hatch-Waxman lawsuit in February 2026 against Torrent Pharmaceuticals and Somerset Therapeutics regarding generic versions of Recorlev. The lawsuit triggers a 30-month stay on FDA approval of the generic ANDAs.
- Generic Competition: Keveyis faces ongoing erosion from generic dichlorphenamide. Recorlev faces potential generic entry pending litigation outcomes.
- Supply Chain: Reliance on single-source suppliers for key APIs and drug products (e.g., Regis for Recorlev API, Taro for Keveyis) creates vulnerability to disruptions.
- Regulatory & Pricing: Exposure to U.S. healthcare reform, including potential Most-Favored-Nation (MFN) pricing models and Medicare negotiation programs, which could impact net revenue.
- Capital Needs: While currently liquid, the company may require additional financing for future growth, which could result in dilution.
Investor Verification Checklist
- Recorlev Patent Litigation Status: Monitor the progress of the lawsuit against Torrent and Somerset to assess the risk of generic entry before 2040.
- Keveyis Market Share: Verify the rate of revenue erosion due to generic competition and the effectiveness of patent appeals.
- XP-8121 Clinical Timeline: Confirm the initiation date and design of the Phase 3 trial scheduled for 2026.
- Debt Covenants: Review the Amended and Restated Credit Agreement for compliance with financial covenants and restrictions on dividends or additional debt.
- Rebate Accruals: Scrutinize the $43.3 million accrued trade discounts and rebates, identified as a critical audit matter, for accuracy in revenue recognition.